Inotuzumab ozogamicin

Inotuzumab ozogamicin
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	CD22
Identifiers
CAS Number	635715-01-4
ATC code	none
Chemical data
Formula	C6518H10002N1738O2036S42
Molar mass	150,000 Daltons[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Inotuzumab ozogamicin is a humanized monoclonal antibody for the treatment of cancers.^[1] The monoclonal antibody is linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).^[2]

This drug was developed by Wyeth.

References

↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Inotuzumab ozogamicin, American Medical Association.
↑ Takeshita, A; Shinjo, K; Yamakage, N; Ono, T; Hirano, I; Matsui, H; Shigeno, K; Nakamura, S; Tobita, T; Maekawa, M (2009). "CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma". British journal of haematology. 146 (1): 34–43. doi:10.1111/j.1365-2141.2009.07701.x. PMID 19388933.

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

v t e Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
"-lizu-" (immune system)	immunosuppressive: Aselizumab, Apolizumab, Benralizumab^†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140^†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412^§ non-immunosuppressive: Ibalizumab^†
"-bazu-" (bacterial)	Tefibazumab^†
"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab^†, Solanezumab, Tanezumab
"-toxazu-" (toxin as target)	Urtoxazumab
"-vizu-" (viral)	Felvizumab, Motavizumab, Palivizumab
"-kizu-" (interleukin as target)	Lebrikizumab
"-anibizu-" (angiogenesis inhibitor)	Ranibizumab
^†Undergoing clinical trials. ^§Never marketed.